CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company’s Board of Directors, effective June 9, 2025. “It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology ...

"Adial's collaboration with Cytel reinforces our commitment to disciplined capital deployment and data-driven execution," said Cary Claiborne, CEO at Adial. "By leveraging advanced analytics and adaptive design, we are in a strong position to generate meaningful clinical data while minimizing time and spend. We believe this strategy materially increases the probability of success for AD04 and creates significant value for patients and shareholders alike." Adial's platform is focused on developing geneticall ...

Group 1 - Castle Biosciences, Inc. will participate in a panel discussion at the 2025 BIO International Convention, focusing on the challenges faced by precision medicine companies in commercializing innovative diagnostic tests [1][2] - The panel titled "Advancing Innovative Risk-Stratification Tests That Impact Treatment Pathway Decisions: Challenges in Overcoming Barriers to Entry" is scheduled for June 17, 2025, from 11 a.m. to 12 p.m. Eastern Time [2] - The session will be moderated by Michael Ryan, J.D., and will include industry leaders discussing strategies for navigating market complexities while improving patient care [2][8] Group 2 - Castle Biosciences is a leading diagnostics company that aims to improve health through innovative tests that guide patient care [5] - The company's current portfolio includes tests for skin cancers, Barrett's esophagus, and uveal melanoma, with ongoing research for additional tests in high clinical need areas [6] - Castle Biosciences emphasizes a patient-first approach in transforming disease management, focusing on the needs of patients, clinicians, employees, and investors [5][6]

Core Insights - Tempus AI, Inc. (NASDAQ: TEM) is a technology company focused on precision medicine, primarily in genomics and data services, with a recent expansion into AI applications for healthcare [1] Company Overview - The company's core business revolves around genomics and data services, which has shown impressive growth [1] - Tempus AI is now integrating artificial intelligence into its healthcare solutions, indicating a strategic shift towards advanced technology applications [1] Growth and Expansion - The expansion into AI for healthcare applications has contributed to the company's growth trajectory, highlighting its commitment to innovation in the medical field [1]

Gold-level Stevie® Award recognizes Maetzold’s transformative leadership in the healthcare industry, including molecular diagnostics and precision medicine FRIENDSWOOD, Texas, June 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been awarded a distinguished Lifetime Achievement Award in the Management: Business Products ...

Bio-Techne (TECH) FY Conference June 03, 2025 03:40 PM ET Speaker0 Thanks everyone for hanging with us towards the end of the day here. And thanks for joining us for the Biotechnology Management Presentation. My name is Matt Larue. Very happy to have CEO Kim Kelderman here and Dave Claire from IR is here as well. So thanks to them for joining us. I have two logistical comments. One, the breakout is in Maher on the Second Floor. And then second, for a list of our research disclosures and conflicts of interes ...

Key Takeaways QGEN partners with Tracer and Foresight to advance MRD testing in oncology clinical trials. New alliances support decentralized, non-invasive diagnostics using QIAGEN's QIAcuity dPCR and ctDNA tests. The partnerships aim to broaden clinical access and enhance QGEN's leadership in personalized cancer care.QIAGEN N.V. (QGEN) announced the expansion of its oncology diagnostics portfolio with two strategic partnerships. The new collaborations with Tracer Biotechnologies and Foresight Diagnostics ...

Core Insights - Incannex Healthcare Inc. has appointed four experts to its IHL-42X Obstructive Sleep Apnea Clinical Advisory Board, enhancing its capabilities in developing treatments for obstructive sleep apnea (OSA) [1][2][4] - The company is preparing to announce Phase 2 topline data for IHL-42X in July 2025 and will initiate a Phase 3 U.S. study later in the year [1][8] - IHL-42X is an oral fixed-dose combination of dronabinol and acetazolamide, designed to target the underlying pathophysiology of OSA [7][10] Company Overview - Incannex is focused on developing combination medicines targeting chronic conditions, including OSA, rheumatoid arthritis, and generalized anxiety disorder [10] - The company is advancing three clinical-stage product candidates, with IHL-42X being the lead program [10] - Incannex aims to address critical gaps in care for conditions that have limited or no approved pharmaceutical treatments [10] Clinical Advisory Board - The newly appointed members include: - Scott A. Sands, Ph.D., an expert in respiratory physiology and engineering [1][5] - Ali Azarbarzin, Ph.D., focusing on the physiological consequences of sleep apnea [2][5] - Lora J. McGill, M.D., FAAN, a neurologist with extensive experience in clinical trials [3][5] - Nancy Collop, M.D., a recognized leader in sleep medicine [4][5] IHL-42X Development - IHL-42X is currently in the RePOSA Phase 2/3 clinical trial, expected to enroll over 560 patients globally [7][8] - Previous trials indicated that IHL-42X reduced the Apnea-Hypopnea Index (AHI) by an average of 51% at the lowest dose [8][9] - The treatment targets two key physiological pathways associated with OSA, potentially benefiting a broader range of patients, including those not classified as obese [9]

Core Insights - Telix Pharmaceuticals Limited is hosting an Investor Day on June 11, 2025, in New York City, focusing on growth opportunities in precision medicine and therapeutic radiopharmaceuticals [1][4] Company Overview - Telix is a biopharmaceutical company dedicated to developing and commercializing therapeutic and diagnostic radiopharmaceuticals, headquartered in Melbourne, Australia, with operations in the U.S., Brazil, Canada, Europe, and Japan [4] - The company is addressing significant unmet medical needs in oncology and rare diseases through its clinical and commercial stage products [4] Event Details - The Investor Day will feature key opinion leaders discussing the clinical utility and opportunities for Telix's theranostic candidates [2] - In-person attendance is available for institutional investors and analysts, with advance registration required [3] Key Opinion Leaders - Dr. Oliver Sartor, an expert in prostate cancer, will discuss TLX591, having published over 500 peer-reviewed articles and led pivotal Phase 3 studies [7] - Dr. John de Groot, a neuro-oncology expert, will present on TLX101, with over 200 peer-reviewed publications and significant involvement in clinical studies [7] - Dr. Joseph Osborne, specializing in renal cancer imaging, will cover TLX250-CDx, focusing on advancing molecular imaging [7]

Core Viewpoint - Tempus AI's stock experienced a significant increase of 15% following positive announcements related to its AI-driven programs, despite facing allegations from short sellers regarding its AI usage [1][2]. Company Developments - Tempus, a precision medicine company utilizing AI, was recently targeted by a short report questioning its AI claims. In response, the company made announcements about two AI initiatives over the weekend, which seemed to mitigate concerns raised by the short seller [2]. - The company updated its AI platform, Tempus One, to include direct access to electronic health records (EHR) systems, enhancing its ability to gather real-time clinical, molecular, and imaging data from millions of patients [3]. - Tempus introduced an initiative called Fuses, aimed at creating an AI-enabled diagnostic platform that offers a comprehensive suite of algorithmic tests to advance precision medicine [5]. Market Reaction - Following the announcements, Tempus AI's stock surged, aligning with a broader market increase in the S&P 500 and Nasdaq Composite [1]. - TD Cowen maintained a buy rating for Tempus, indicating confidence in the company's prospects despite the short seller's allegations [5].